Moleculin Biotech Q4 EPS $(26.06) Misses $(11.60) Estimate

Moleculin Biotech (NASDAQ: MBRX) reported a Q4 loss of $(26.06) per share, significantly missing the analyst consensus estimate of $(11.60) by 124.75%. This represents a 181.73% increase in losses compared to $(9.25) per share from the same period last year.